AtriCure (ATRC) Cash & Equivalents (2010 - 2026)

AtriCure (ATRC) has 17 years of Cash & Equivalents data on file, last reported at $146.2 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 46.33% year-over-year to $146.2 million in Q1 2026; TTM through Mar 2026 was $146.2 million, a 46.33% increase from a year earlier, with the FY2025 full-year figure at $167.4 million, up 36.43% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $146.2 million, down from $167.4 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ATRC reached as high as $167.4 million in Q4 2025 and fell as low as $28.1 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $94.3 million across 5 years, with a median of $84.3 million in 2023.
• Across the five-year window, Cash & Equivalents sank 67.04% in 2022 and surged 174.83% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $58.1 million in 2022, then surged by 45.11% to $84.3 million in 2023, then surged by 45.56% to $122.7 million in 2024, then surged by 36.43% to $167.4 million in 2025, then dropped by 12.7% to $146.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $146.2 million in Q1 2026, $167.4 million in Q4 2025, and $147.9 million in Q3 2025.